Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.

Gibson CJ, Lindsley RC, Tchekmedyian V, Mar BG, Shi J, Jaiswal S, Bosworth A, Francisco L, He J, Bansal A, Morgan EA, Lacasce AS, Freedman AS, Fisher DC, Jacobsen E, Armand P, Alyea EP, Koreth J, Ho V, Soiffer RJ, Antin JH, Ritz J, Nikiforow S, Forman SJ, Michor F, Neuberg D, Bhatia R, Bhatia S, Ebert BL.

J Clin Oncol. 2017 May 10;35(14):1598-1605. doi: 10.1200/JCO.2016.71.6712. Epub 2017 Jan 9.

2.

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.

Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohani AR, Zain J, Rosen ST, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P.

J Clin Oncol. 2017 Jan;35(1):24-31. Epub 2016 Oct 24.

3.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Jul 11;30(1):183. doi: 10.1016/j.ccell.2016.06.008. Epub 2016 Jul 11. No abstract available.

4.

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.

Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, Fisher DC, Freedman AS, Jacobson CA, Armand P, Abramson JS, Arnason JE, Kipps TJ, Fein J, Fernandes S, Hanna J, Ritz J, Kim HT, Brown JR.

Blood. 2016 Jul 14;128(2):195-203. doi: 10.1182/blood-2016-03-707133. Epub 2016 May 31.

5.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Apr 11;29(4):574-586. doi: 10.1016/j.ccell.2016.03.008. Erratum in: Cancer Cell. 2016 Jul 11;30(1):183.

6.

Is There a Best Initial Treatment for a New Patient With Low Grade Follicular Lymphoma.

Jacobson CA, Freedman AS.

Curr Hematol Malig Rep. 2016 Jun;11(3):218-23. doi: 10.1007/s11899-016-0321-6. Review.

PMID:
26995595
7.

A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma.

Armand P, Redd R, Bsat J, Mayuram S, Giardino A, Fisher DC, LaCasce AS, Jacobson C, Davids MS, Brown JR, Weng L, Wilkins J, Faham M, Freedman AS, Joyce R, Jacobsen ED.

Br J Haematol. 2016 Apr;173(1):89-95. doi: 10.1111/bjh.13929. Epub 2016 Jan 5.

PMID:
26729345
8.

Rethinking Prognosis and Therapy for Follicular Lymphoma.

Jacobson CA, Freedman AS.

J Clin Oncol. 2015 Aug 10;33(23):2489-91. doi: 10.1200/JCO.2015.62.3256. Epub 2015 Jul 13. No abstract available.

PMID:
26169620
9.

Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia.

Brown JR, Tesar B, Yu L, Werner L, Takebe N, Mikler E, Reynolds HM, Thompson C, Fisher DC, Neuberg D, Freedman AS.

Leuk Lymphoma. 2015;56(12):3336-42. doi: 10.3109/10428194.2015.1048441. Epub 2015 Jun 18.

PMID:
25971907
10.

Is observation dead in follicular lymphoma? Still appropriate.

Jacobson CA, Freedman AS.

J Natl Compr Canc Netw. 2015 Mar;13(3):367-70. Review.

PMID:
25736012
11.

Early lymphoid lesions: conceptual, diagnostic and clinical challenges.

Ganapathi KA, Pittaluga S, Odejide OO, Freedman AS, Jaffe ES.

Haematologica. 2014 Sep;99(9):1421-32. doi: 10.3324/haematol.2014.107938. Review.

12.

Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma.

Jacobsen E, Pozdnyakova O, Redd R, Fisher DC, Dorfman DM, Dal Cin P, LaCasce A, Armand P, Hochberg E, Cote G, Shahsafaei A, Neuberg D, Brown JR, Freedman AS.

Leuk Lymphoma. 2015 Apr;56(4):993-8. doi: 10.3109/10428194.2014.941835. Epub 2014 Aug 20.

PMID:
25012943
13.

Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphoma.

Rendleman J, Antipin Y, Reva B, Adaniel C, Przybylo JA, Dutra-Clarke A, Hansen N, Heguy A, Huberman K, Borsu L, Paltiel O, Ben-Yehuda D, Brown JR, Freedman AS, Sander C, Zelenetz A, Klein RJ, Shao Y, Lacher M, Vijai J, Offit K, Kirchhoff T.

PLoS One. 2014 Jul 10;9(7):e101685. doi: 10.1371/journal.pone.0101685. eCollection 2014.

14.

Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.

Levy R, Ganjoo KN, Leonard JP, Vose JM, Flinn IW, Ambinder RF, Connors JM, Berinstein NL, Belch AR, Bartlett NL, Nichols C, Emmanouilides CE, Timmerman JM, Gregory SA, Link BK, Inwards DJ, Freedman AS, Matous JV, Robertson MJ, Kunkel LA, Ingolia DE, Gentles AJ, Liu CL, Tibshirani R, Alizadeh AA, Denney DW Jr.

J Clin Oncol. 2014 Jun 10;32(17):1797-803. doi: 10.1200/JCO.2012.43.9273. Epub 2014 May 5.

15.

Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma.

Fanale M, Assouline S, Kuruvilla J, Solal-Céligny P, Heo DS, Verhoef G, Corradini P, Abramson JS, Offner F, Engert A, Dyer MJ, Carreon D, Ewald B, Baeck J, Younes A, Freedman AS.

Br J Haematol. 2014 Jan;164(2):258-65. doi: 10.1111/bjh.12630. Epub 2013 Nov 13.

16.

One size does not fit all in follicular lymphoma.

Jacobson CA, Freedman AS.

J Clin Oncol. 2013 Sep 20;31(27):3307-8. doi: 10.1200/JCO.2013.50.0454. Epub 2013 Aug 19. No abstract available.

PMID:
23960176
17.

Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma.

Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman AS.

Br J Haematol. 2013 Oct;163(1):123-6. doi: 10.1111/bjh.12439. Epub 2013 Jun 25. No abstract available.

PMID:
23795711
18.

A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

Brown JR, Messmer B, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, LaCasce AS, Armand P, Jacobsen E, Dalton V, Tesar B, Fernandes SM, McDonough S, Ritz J, Rassenti L, Kipps TJ, Neuberg D, Freedman AS.

Haematologica. 2013 Jun;98(6):964-70. doi: 10.3324/haematol.2013.086207. Epub 2013 May 3.

19.

First-line treatment of indolent lymphoma: axing CHOP?

Jacobson CA, Freedman AS.

Lancet. 2013 Apr 6;381(9873):1163-5. doi: 10.1016/S0140-6736(12)61965-5. Epub 2013 Feb 20. No abstract available.

PMID:
23433738
20.

Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era.

Armand P, Welch S, Kim HT, LaCasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Coughlin E, Freedman AS, Chen YB.

Br J Haematol. 2013 Mar;160(5):608-17. doi: 10.1111/bjh.12176. Epub 2012 Dec 29.

PMID:
23278720
21.

Early stage follicular lymphoma, current management and controversies.

Jacobson CA, Freedman AS.

Curr Opin Oncol. 2012 Sep;24(5):475-9. doi: 10.1097/CCO.0b013e328356898b. Review.

PMID:
22820411
22.

Primary bone lymphoma involving bilateral tibia.

Giardino AA, Shinagare AB, Shinagare SA, Dewar R, Weckstein D, Mauch P, Ramaiya NH, Freedman AS.

Am J Hematol. 2012 Sep;87(9):924-5. doi: 10.1002/ajh.23245. Epub 2012 May 28. No abstract available.

23.

Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia.

Brown JR, Hanna M, Tesar B, Werner L, Pochet N, Asara JM, Wang YE, Dal Cin P, Fernandes SM, Thompson C, Macconaill L, Wu CJ, Van de Peer Y, Correll M, Regev A, Neuberg D, Freedman AS.

Clin Cancer Res. 2012 Jul 15;18(14):3791-802. doi: 10.1158/1078-0432.CCR-11-2342. Epub 2012 May 23.

24.

Germline copy number variation associated with Mendelian inheritance of CLL in two families.

Brown JR, Hanna M, Tesar B, Pochet N, Vartanov A, Fernandes SM, Werner L, Ash M, Roden CA, MacConaill L, Hainz U, Longtine J, Wang YE, Correll M, Van de Peer Y, Regev A, Wu C, Neuberg D, Freedman AS.

Leukemia. 2012 Jul;26(7):1710-3. doi: 10.1038/leu.2012.33. Epub 2012 Feb 7. No abstract available.

PMID:
22382893
25.

Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant.

Lane AA, Armand P, Feng Y, Neuberg DS, Abramson JS, Brown JR, Fisher DC, LaCasce AS, Jacobsen ED, McAfee SL, Spitzer TR, Freedman AS, Chen YB.

Leuk Lymphoma. 2012 Jun;53(6):1130-6. doi: 10.3109/10428194.2011.645208. Epub 2012 Jan 3.

26.

Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy.

Fox AM, Dosoretz AP, Mauch PM, Chen YH, Fisher DC, LaCasce AS, Freedman AS, Silver B, Ng AK.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):277-83. doi: 10.1016/j.ijrobp.2011.05.078. Epub 2011 Oct 20.

PMID:
22019238
27.

Expression of mesenchyme-specific gene signatures by follicular dendritic cells: insights from the meta-analysis of microarray data from multiple mouse cell populations.

Mabbott NA, Kenneth Baillie J, Kobayashi A, Donaldson DS, Ohmori H, Yoon SO, Freedman AS, Freeman TC, Summers KM.

Immunology. 2011 Aug;133(4):482-98. doi: 10.1111/j.1365-2567.2011.03461.x. Epub 2011 Jun 3.

28.

Early initial therapy of advanced follicular lymphoma: the need for vigilance.

Sweetenham JW, Freedman AS.

Leuk Lymphoma. 2011 Mar;52(3):355-7. doi: 10.3109/10428194.2010.551574. No abstract available.

PMID:
21323517
29.

(90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.

Abou-Nassar KE, Stevenson KE, Antin JH, McDermott K, Ho VT, Cutler CS, LaCasce AS, Jacobsen ED, Fisher DC, Soiffer RJ, Alyea EP, Koreth J, Freedman AS.

Bone Marrow Transplant. 2011 Dec;46(12):1503-9. doi: 10.1038/bmt.2010.339. Epub 2011 Jan 24.

30.

A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome.

Jacobsen ED, Kim HT, Ho VT, Cutler CS, Koreth J, Fisher DC, Armand P, Alyea EP, Freedman AS, Soiffer RJ, Antin JH.

Ann Oncol. 2011 Jul;22(7):1608-13. doi: 10.1093/annonc/mdq698. Epub 2011 Jan 20.

31.

A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.

Brown JR, Abramson J, Hochberg E, Mikler E, Dalton V, Werner L, Reynolds H, Thompson C, McDonough SM, Kuang Y, Ritz J, Neuberg D, Freedman AS.

Leukemia. 2010 Nov;24(11):1972-5. doi: 10.1038/leu.2010.199. Epub 2010 Sep 16. No abstract available.

32.

Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization.

Setlur SR, Ihm C, Tchinda J, Shams S, Werner L, Cho EK, Thompson C, Phillips K, Rassenti LZ, Kipps TJ, Neuberg D, Freedman AS, Lee C, Brown JR.

Br J Haematol. 2010 Nov;151(4):336-45. doi: 10.1111/j.1365-2141.2010.08341.x. Epub 2010 Aug 31.

33.

Down-regulation of CD9 expression and its correlation to tumor progression in B lymphomas.

Yoon SO, Zhang X, Freedman AS, Zahrieh D, Lossos IS, Li L, Choi YS.

Am J Pathol. 2010 Jul;177(1):377-86. doi: 10.2353/ajpath.2010.100048. Epub 2010 Jun 21.

34.

Epstein-barr virus-associated diffuse large B-cell lymphoma in an immunocompetent woman.

Pozdnyakova O, Spieler PJ, Abraham J, Freedman AS, Kutok JL.

J Clin Oncol. 2010 Feb 10;28(5):e75-8. doi: 10.1200/JCO.2009.23.1423. Epub 2009 Nov 16. No abstract available.

PMID:
19917837
35.

ASCT in follicular lymphoma.

Brown JR, Freedman AS.

Nat Rev Clin Oncol. 2009 Jul;6(7):380-2. doi: 10.1038/nrclinonc.2009.87. No abstract available.

PMID:
19561632
36.

Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.

Friedberg JW, Kelly JL, Neuberg D, Peterson DR, Kutok JL, Salloum R, Brenn T, Fisher DC, Ronan E, Dalton V, Rich L, Marquis D, Sims P, Rothberg PG, Liesveld J, Fisher RI, Coffman R, Mosmann T, Freedman AS.

Br J Haematol. 2009 Aug;146(3):282-91. doi: 10.1111/j.1365-2141.2009.07773.x. Epub 2009 Jun 10.

37.

A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.

Brown JR, Friedberg JW, Feng Y, Scofield S, Phillips K, Dal Cin P, Joyce R, Takvorian RW, Fisher DC, Fisher RI, Liesveld J, Marquis D, Neuberg D, Freedman AS.

Br J Haematol. 2009 Jun;145(6):741-8. doi: 10.1111/j.1365-2141.2009.07677.x. Epub 2009 Mar 30.

38.

Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.

Armand P, Gannamaneni S, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Antin JH.

J Clin Oncol. 2008 Dec 10;26(35):5767-74. doi: 10.1200/JCO.2008.17.7279. Epub 2008 Nov 10.

39.

Systematic genomic screen for tyrosine kinase mutations in CLL.

Brown JR, Levine RL, Thompson C, Basile G, Gilliland DG, Freedman AS.

Leukemia. 2008 Oct;22(10):1966-9. doi: 10.1038/leu.2008.222. Epub 2008 Aug 28. No abstract available.

40.

Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders.

Brown JR, Neuberg D, Phillips K, Reynolds H, Silverstein J, Clark JC, Ash M, Thompson C, Fisher DC, Jacobsen E, LaCasce AS, Freedman AS.

Br J Haematol. 2008 Nov;143(3):361-8. doi: 10.1111/j.1365-2141.2008.07355.x. Epub 2008 Aug 20. Erratum in: Br J Haematol. 2009 May;145(4):551.

41.

Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma.

Luthy SK, Ng AK, Silver B, Degnan KO, Fisher DC, Freedman AS, Mauch PM.

Ann Oncol. 2008 Dec;19(12):2043-7. doi: 10.1093/annonc/mdn529. Epub 2008 Jul 22.

42.

Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma.

LaCasce AS, Freedman AS.

Semin Hematol. 2008 Apr;45(2):85-9. doi: 10.1053/j.seminhematol.2008.02.004. Review.

PMID:
18381102
43.

Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.

Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP.

Biol Blood Marrow Transplant. 2008 Apr;14(4):418-25. doi: 10.1016/j.bbmt.2008.01.008.

44.

Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission.

Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P, Nadler LM, Freedman AS.

Biol Blood Marrow Transplant. 2007 Sep;13(9):1057-65. Epub 2007 Jul 16.

45.

Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up.

Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J, Gribben JG, Mauch PM, Lister TA, Freedman AS.

J Clin Oncol. 2007 Jun 20;25(18):2554-9. Epub 2007 May 21.

PMID:
17515573
46.

Novel presentation of intraneural nodular fasciitis of the sciatic nerve.

Parrett BM, Orgill DP, Marsee DK, Freedman AS, Raut CP.

J Peripher Nerv Syst. 2007 Mar;12(1):61-3. No abstract available.

PMID:
17374106
47.

Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma.

Friedberg JW, Freedman AS.

Curr Treat Options Oncol. 2006 Jul;7(4):276-84. Review.

PMID:
16916488
48.

Non-transplant-related treatment options in follicular lymphoma.

Freedman AS.

Biol Blood Marrow Transplant. 2006 Jan;12(1 Suppl 1):53-8. Review. No abstract available.

49.

Biology and management of histologic transformation of indolent lymphoma.

Freedman AS.

Hematology Am Soc Hematol Educ Program. 2005:314-20.

PMID:
16304397
50.

Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.

Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC, Freedman AS, Mauch P, Schlossman R, Sequist LV, Soiffer RJ, Marshall B, Neuberg D, Ritz J, Nadler LM.

Blood. 2005 Dec 15;106(13):4389-96. Epub 2005 Aug 30.

Supplemental Content

Loading ...
Support Center